Clinical Trial Update: Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sorafenib plus arsenic-based treatment for recurrent hepatocellular carcinoma after liver transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• arsenical

Snippet

Sponsor: Zhejiang University | Conditions: HCC | Phase 2 | Status: UNKNOWN